DC Field | Value | Language |
---|---|---|
dc.contributor.author | V K Sharma | - |
dc.contributor.author | D T Hung | - |
dc.contributor.author | K C Lee | - |
dc.contributor.author | P Thanigaimalai | - |
dc.contributor.author | Jong Soon Kang | - |
dc.contributor.author | Hwan Mook Kim | - |
dc.contributor.author | S H Jung | - |
dc.date.accessioned | 2017-04-19T09:24:51Z | - |
dc.date.available | 2017-04-19T09:24:51Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 2040-2503 | - |
dc.identifier.uri | 10.1039/c0md00219d | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/10278 | - |
dc.description.abstract | To investigate the effect of isosteric replacement of phenyl with heteroaromatics of 4-phenyl-N-arylsulfonylimidazolones (1-4) as broad and potent anticancer agents, a series of 4-furyl (5a-e, 7a-c) or thienyl-N- arylsulfonylimidazolones (6a-e) were designed and synthesized to evaluate their in vitro anticancer activity against HCT116, A549 and NCI-H460 cancer cell lines. Replacement of phenyl with furyl or thienyl slightly reduced the activity, however, these analogs showed comparable activity to doxorubicin. The thienyl analogs exhibited more potent activity than furyl analogs due to their more isosteric similarity with the phenyl moiety. In addition, the carbamate derivatives (5a-e and 6a-e) of both the analogs had better activities than the carbamoyl derivatives (7a-c). Therefore, the size and planarity of the aryl motif at 4-position of N-arylsulfonylimidazolones are crucial for their anticancer activity. | - |
dc.publisher | Royal Soc Chemistry | - |
dc.title | Effect of the isosteric replacement of the phenyl motif with furyl (or thienyl) of 4-phenyl-N-arylsulfonylimidazolones as broad and potent anticancer agents | - |
dc.title.alternative | Effect of the isosteric replacement of the phenyl motif with furyl (or thienyl) of 4-phenyl-N-arylsulfonylimidazolones as broad and potent anticancer agents | - |
dc.type | Article | - |
dc.citation.title | Medchemcomm | - |
dc.citation.number | 8 | - |
dc.citation.endPage | 734 | - |
dc.citation.startPage | 731 | - |
dc.citation.volume | 2 | - |
dc.contributor.affiliatedAuthor | Hwan Mook Kim | - |
dc.contributor.alternativeName | Sharma | - |
dc.contributor.alternativeName | Hung | - |
dc.contributor.alternativeName | 이기철 | - |
dc.contributor.alternativeName | Thanigaimalai | - |
dc.contributor.alternativeName | 강종성 | - |
dc.contributor.alternativeName | 김환묵 | - |
dc.contributor.alternativeName | 정상훈 | - |
dc.identifier.bibliographicCitation | Medchemcomm, vol. 2, no. 8, pp. 731-734 | - |
dc.identifier.doi | 10.1039/c0md00219d | - |
dc.description.journalClass | N | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.